LEO Pharma News - LARVOL Sigma

«1 2...5 6 7 8 91011 12 13 14 15...48 49 »

|||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Journal: Ein m (Pubmed Central) - Mar 24, 2023
No abstract available

|||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Journal: A possible case of brodalumab-induced ichthyosis. (Pubmed Central) - Mar 24, 2023
No abstract available No abstract available

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis, adriforant (ZPL 3893787) / Novartis
Preclinical, Journal: Adriforant is a functional antagonist of histamine receptor 4 and attenuates itch and skin inflammation in mice. (Pubmed Central) - Mar 21, 2023
The effects observed in mice, however, did not translate to clinical efficacy in patients as the Ph2b clinical trial with adriforant did not meet pre-specified efficacy endpoints. Given the complex pathogenesis of AD, antagonism of histamine receptor 4 alone appears insufficient to reduce disease severity in AD patients, despite the effects seen in mouse models.

|||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal: Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. (Pubmed Central) - Mar 21, 2023
P3
Given the complex pathogenesis of AD, antagonism of histamine receptor 4 alone appears insufficient to reduce disease severity in AD patients, despite the effects seen in mouse models. Our findings indicate specific targeting of the interleukin 13 cytokine with tralokinumab can directly and/or indirectly improve microbial dysbiosis seen in AD skin.

|||||||||| FDA event, Reimbursement, Journal, Medicare: Adoption of newly FDA-approved targeted immunomodulatory therapies by dermatologists: a cross-sectional analysis of Medicare Part D claims from 2013 to 2018. (Pubmed Central) - Mar 21, 2023
We believe these data show that the adoption of novel biologic treatments for psoriasis by dermatologists to Medicare beneficiaries may be associated with clinician experience and practice volume. Additionally, we identified low absolute numbers of dermatologists prescribing biologics overall in non-metropolitan areas, which may represent delayed access to novel psoriasis treatments for many Medicare beneficiaries.

|||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin, Cosentyx (secukinumab) / Novartis
Journal, Real-world evidence, Real-world: Blocking Interleukin-17 in Psoriasis: Real-world Experience from the PsoPlus Cohort. (Pubmed Central) - Mar 20, 2023
Treatment modifications were mainly performed in case of insufficient response, primarily via switch and dose escalation, and least frequently in ixekizumab patients. C might rationalize clinical decision-making; however, there is need for standardized algorithms to corroborate its use.

|||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Biomarker, Journal, Real-world evidence, Real-world: Brodalumab in plaque psoriasis: real world data on effectiveness, safety, and clinical predictive factors of initial response and drug survival over a period of 104?weeks. (Pubmed Central) - Mar 20, 2023
C might rationalize clinical decision-making; however, there is need for standardized algorithms to corroborate its use. Our study confirms the high effectiveness and good safety profile of brodalumab in the real-world setting.

|||||||||| orismilast oral (LEO 32731) / UNION Therap
Journal: Pharmacology of orismilast, a potent and selective PDE4 inhibitor. (Pubmed Central) - Mar 20, 2023
Orismilast displayed selective and potent PDE4 inhibition and broad-spectrum anti-inflammatory activity in several pre-clinical models. The results of the study support clinical development of oral orismilast as a novel treatment option for CISD including psoriasis, atopic dermatitis, and hidradenitis suppurativa.

|||||||||| orismilast oral (LEO 32731) / UNION Therap
Journal: Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets. (Pubmed Central) - Mar 20, 2023
Orismilast MR had similar PK properties and fewer GI disorders compared to the IR formulation in healthy participants. Future development of orismilast will be based on the MR formulation.

|||||||||| Naphcon-A (naphazoline HCl) / Novartis, arbekacin (NPC-14) / Nobelpharma, Fucidin (fusidic acid) / LEO Pharma
Journal: Effects of thiram exposure on liver metabolism of chickens. (Pubmed Central) - Mar 17, 2023
Taken together, this research showed that thiram exposure significantly altered hepatic metabolism in chickens. Moreover, this study also provided a basis for regulating the use and disposal of thiram to ensure environmental quality and poultry health.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Preclinical, Journal: A Mouse Model of MC903-Induced Atopic Dermatitis. (Pubmed Central) - Mar 14, 2023
Current Protocols published by Wiley Periodicals LLC. Basic Protocol: Topical application of MC903 induces AD-like skin inflammation Support Protocol 1: Measurement of ear skin thickness Support Protocol 2: Itch assessment Support Protocol 3: Dissection of ear skin and ear draining lymph nodes Support Protocol 4: Histological evaluation and quantification Support Protocol 5: Preparation of single-cell suspension from ear skin and draining lymph nodes for the assessment of inflammatory immune cell infiltration using flow cytometry.

||||||||||  Innohep (tinzaparin) / LEO Pharma
Enrollment open, Trial initiation date, Metastases:  PROTINCOL: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 14, 2023
P3, N=526, Recruiting,  Sponsor: Galician Research Group on Digestive Tumors
Basic Protocol: Topical application of MC903 induces AD-like skin inflammation Support Protocol 1: Measurement of ear skin thickness Support Protocol 2: Itch assessment Support Protocol 3: Dissection of ear skin and ear draining lymph nodes Support Protocol 4: Histological evaluation and quantification Support Protocol 5: Preparation of single-cell suspension from ear skin and draining lymph nodes for the assessment of inflammatory immune cell infiltration using flow cytometry. Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Mar 2023

|||||||||| patidegib topical (IPI-926 topical) / Bridge Biotherap, LEO Pharma
Journal: Recent advances in chemical composition and transdermal delivery systems for topical bio-actives in skin cancer. (Pubmed Central) - Mar 11, 2023
In particular, significant studies have been made, including modification of bio-actives, permeability enhancers, incorporation of advanced nano and microcarriers, and physical enhancement devices. This critical review summarizes the advancement in the chemical composition of bioactives used in skin cancer, such as sinecatechins, BIL-010t, patidegib, gingerol, curcumin, remetinostat, epigallocatechin-3-gallate, etc. Furthermore, this review, specifically addresses the progress in transdermal delivery systems for melanoma and non-melanoma cancer therapy, emphasizing advances in physical and chemical penetration enhancement and nanocarrier-assisted transdermal systems.

|||||||||| Induction Cost per Responder of Biologic Therapies for Plaque Psoriasis in Canada () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1167;
Despite the availability of various biologic and SEB therapies for plaque psoriasis in Canada, the range of CPR estimates vary significantly, with brodalumab having the lowest CPR across all PASI scores during the induction period. Using therapies with more favorable CPR may translate into cost-saving opportunities.

|||||||||| Cost-per-Responder for Biologic Drugs Used in the Treatment of Plaque Psoriasis in France and Germany () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_186;
Over a one-year time-horizon, risankizumab and brodalumab were the most cost-effective biologics in France and Germany within moderate-to-severe plaque psoriasis. Brodalumab was most cost-effective within the anti-IL17s, including the newly launched bimekizumab.

||||||||||  ARGX-112 / LEO Pharma
Enrollment closed:  A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD (clinicaltrials.gov) -  Mar 8, 2023
P2, N=13, Active, not recruiting,  Sponsor: LEO Pharma
Brodalumab was most cost-effective within the anti-IL17s, including the newly launched bimekizumab. Recruiting --> Active, not recruiting

|||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Biologics in the management of childhood atopic dermatitis. (Pubmed Central) - Mar 7, 2023
Recruiting --> Active, not recruiting No abstract available

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Journal: IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin. (Pubmed Central) - Mar 7, 2023
No abstract available A network comprising IL-31-expressing macrophages, TSLP, periostin, and basophils plays a significant role in AD itch.

|||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Journal: Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study. (Pubmed Central) - Mar 7, 2023
Unlike anxiety symptoms, depressive symptoms did not resolve completely with brodalumab treatment. Patients with psoriasis having depressive symptoms may require long-term treatment.

|||||||||| Innohep (tinzaparin) / LEO Pharma
Journal: Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients. (Pubmed Central) - Mar 7, 2023
Dosing of tinzaparin adjusted for actual bodyweight in obese patients achieved anti-Xa activity in the target range for most patients, without accumulation or overdosing. In addition, there is a significant difference in thrombin generation depending on the injection site.

|||||||||| betamethasone/calcipotriol (BFH 772) / Novartis, Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Clinical, Observational data, Journal: Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar (Pubmed Central) - Mar 6, 2023
In addition, there is a significant difference in thrombin generation depending on the injection site. This study demonstrated the effectiveness, rapid onset of action, good tolerability, and good safety profile of the Cal/BD aerosol foam in patients with scalp psoriasis treated in a real-world setting.

|||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Journal: Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab. (Pubmed Central) - Mar 4, 2023
This study demonstrated the effectiveness, rapid onset of action, good tolerability, and good safety profile of the Cal/BD aerosol foam in patients with scalp psoriasis treated in a real-world setting. No abstract available

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Journal: Therapeutic effects and mechanisms of Ku-Gan formula on atopic dermatitis: A pilot clinical study and modular pharmacology analysis with animal validation. (Pubmed Central) - Mar 4, 2023
These results showed that KG is a safe and effective topical treatment for AD with low recurrence. In addition, our study identified potential molecular pathways and therapeutic candidate targets of the KG formula, providing evidence for its clinical applicability in AD.

|||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron, Blenrep (belantamab mafodotin) / GSK
Journal, Adverse events: Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management. (Pubmed Central) - Mar 4, 2023
In more severe cases, additional anti-inflammatory therapy, with corticosteroid eye drops or ointments, or topical calcineurin inhibitors-such as tacrolimus or ciclosporin-were required. Patients with resistant or refractory multiple myeloma treated with belantamab mafodotin often developed keratopathy, which could necessitate contact lens fitting, or for cycles of belantamab mafodotin to be delayed.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis, Ocaliva (obeticholic acid) / Intercept
Topical vitamin D3 treatment increases bile acids that induce systemic adipose loss by sebum hypersecretion in high fat diet-fed mice () - Mar 4, 2023 - Abstract #ISID2023ISID_1681;
This study reveals that topical MC903 treatment increases serum bile acids, which in turn stimulate sebum TG secretion that causes adipose loss. Thus, topical MC903 treatment might represent a novel therapeutic strategy in regulating lipid metabolism by throwing out body lipids through the skin.

|||||||||| Jakafi (ruxolitinib) / Novartis, Incyte, Dovonex (calcipotriol) / LEO Pharma, Novartis
Ruxolitinib reduces inflammation, itch and immune subsets -DETCs and macrophages in a mouse MC903 dermatitis model () - Mar 4, 2023 - Abstract #ISID2023ISID_1679;
Taken together, ruxolitinib treated mice showed a reduction of inflammatory and pruritis in the MC903 dermatitis model. This present study corroborates with data in human clinical trials where AD patients have reduced SCORAD, pruritis and inflammatory phenotypes.

|||||||||| Vtama (tapinarof) / Roivant, Japan Tobacco
Benvitimod alleviates the Type 2 immune responses in atopic dermatitis by restraining group 2 innate lymphoid cells () - Mar 4, 2023 - Abstract #ISID2023ISID_1355;
In addition, we found that BVM also reduced the expression of IL-33 in vitro , and BVM played the role via AhR-OVOL1 signaling. Taken together, BVM can alleviates the Type 2 immune responses in atopic dermatitis by restraining ILC2 cells and reduce the Th2-associated cytokines, IL-4, IL-13 and IL-33.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Elevation of TARC by anti-IL-31 receptor antibody in a murine atopic dermatitis model () - Mar 4, 2023 - Abstract #ISID2023ISID_1342;
To clarify this mechanism, using a calcipotriol (MC903)-induced AD mouse model, we found increased expression of IL-31 in the skin and increased levels of TARC in the serum...Taken together, we demonstrated the increase level of TARC in the serum and skin with anti-IL-31RA treatment in a murine AD model. Further study is needed to identify the TARC-producing dermal cells, such as dendritic cells, macrophages, fibroblasts, and endothelial cells, during anti-IL-31RA antibody treatment.

|||||||||| Eucrisa (crisaborole) / Pfizer
Crisaborole inhibits itch and pain by preventing neutrophil infiltration () - Mar 4, 2023 - Abstract #ISID2023ISID_1334;
Additionally, using the cheek skin injection model, we found that S100A8/A9 enhanced not only itch-related behaviors evoked by histamine or chloroquine, but also pain-related behaviors. These findings suggest that the PDE-4 inhibitor reduces itch and pain in atopic dermatitis, in part by inhibiting infiltration of S100A8/9-containing neutrophils.

|||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Dovonex (calcipotriol) / LEO Pharma, Novartis
Epidermis-intrinsic N6-methyladenosine modification dampens skin inflammation () - Mar 4, 2023 - Abstract #ISID2023ISID_1265;
The results of MeRIP-seq suggested that reprogramming of fatty acid metabolism in KCs might play an important role in the maintenance of skin immune homeostasis by METTL3. This study provides a solid foundation for further research on the effect of m 6 A modification in KCs in the pathogenesis of skin inflammation, such as psoriasis and AD.

|||||||||| imatinib / Generic mfg.
Topical application of imatinib mesylate suppresses vitamin D3 analog-induced dermatitis in balb/c mice () - Mar 4, 2023 - Abstract #ISID2023ISID_1061;
IMT suppressed the number of infiltrating cells (CD4+ T cells, eosinophils, basophils) and the expression of IL-13, IL-33, and TSLP in a MC903-induced, murine AD model and inhibited TNF-?/IL-4-induced TSLP expression via downregulation of ERK phosphorylation in MKCs. From the results of this experiment, IMT reduced the skin symptoms in a MC903-induced, murine AD model, suggesting that it may have potential as a new treatment for AD.

|||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
Incidence of conjunctivitis adverse event with biological therapies in atopic dermatitis: A systematic review and meta-analysis () - Mar 4, 2023 - Abstract #ISID2023ISID_1015;
Out of 17 studies, 12 evaluated the efficacy of Dupilumab and 2 tested Lebrikizumab and 3 Tralokinumab. There is a high risk of developing conjunctivitis among patients undergoing biological therapies for atopic dermatitis.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
TRPV3 modulates mast cells biological activity via stimulating IL33 release in atopic dermatitis () - Mar 4, 2023 - Abstract #ISID2023ISID_786;
With bioinformatics investigation, we found that mast cells of TRPV3 KO mice infiltrated less in the dermis than those of wild type (WT) controls with MC903 treatment...This work expanded our understanding of TRP channels regulating itching cytokines and neuro-immunity network. More importantly, our findings provide a new theoretical basis for TRPV3 inhibitors to treat itch and inflammation in atopic dermatitis.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Acute stress aggravates itch in experimental AD and drives changes in trigeminal ganglion neurons related to neuroinflammation () - Mar 4, 2023 - Abstract #ISID2023ISID_649;
TGs from stressed MC903-AD mice display elevated genes related to neutrophil activation (Ngp, Camp, Lcn2) and voltage-gated ion channel (Kcne3) compared to those from non-stressed MC903-AD mice. From these results we can uncover potential targets for controlling acute stress-aggravated itch in AD.

|||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
The clinical and immunological features of immune checkpoint inhibitors-related psoriasis () - Mar 4, 2023 - Abstract #ISID2023ISID_632;
Transcriptomic and immune phenotyping showed a predominant Th17 inflammatory response. A therapeutic targeting Th17 pathway may be an optional treatment for refractory ICI-psoriasis.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
The role of transient receptor potential vanilloid 4 (TRPV4) channels in atopic dermatitis () - Mar 4, 2023 - Abstract #ISID2023ISID_616;
In conclusion, we showed that TRPV4 regulates the MC903-induced atopic dermatitis-like skin inflammation via the production of TSLP and inflammation in mice. Future work will focus on immunological aspects of TRPV4 regulation in atopic dermatitis, particularly type 2 inflammation.

|||||||||| PRELP negatively regulate IL-17A mediated proliferation and inflammatory in psoriasis () - Mar 4, 2023 - Abstract #ISID2023ISID_582;
In conclusion, We postulate than PRELP is a negative regulator in IL-17A mediated signal in psoriasis. PRELP is a potential target for the treatment of psoriasis.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Fucosyltransferase 1 plays a protective role in the development of atopic dermatitis-like disease in mice (ePoster Stage 5) - Mar 4, 2023 - Abstract #ISID2023ISID_525;
Furthermore, using a MC903-induced AD-like mouse model, Fut1-deficient mice showed higher serum IgE levels, compared to WT mice...Infiltration of CD4 + T cells, Gr-1 + cells (neutrophils), and mast cells into lesion skin was significantly higher in Fut1-deficient mice than in WT mice. Thus, these findings reveal that barrier dysfunction in ?(1,2)

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
A novel IL-31-generating mechanism in atopic dermatitis: essential roles of macrophages in cooperation with basophils, thymic stromal lymphopoietin and periostin (ePoster Stage 4) - Mar 4, 2023 - Abstract #ISID2023ISID_494;
Ex vivo analysis with murine peritoneal macrophages showed that macrophages produced IL-31 when stimulated by basophils, TSLP and periostin, but not by IL-4/13 or IL-33. IL-31 appears to be mostly produced by M2 type macrophages in cooperation with basophils, TSLP and periostin in AD.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Acid mantle of the stratum corneum is a shield against bacterial entry into the underlying epidermal layers (Room D (Ohgi) ) - Mar 4, 2023 - Abstract #ISID2023ISID_372;
Moreover, to investigate the microbial behavior in detail, S. aureus was inoculated to the mice with thickened SC due to topical application of MC903, which induces atopic dermatitis-like inflammation...The more basic buffer applied, the more severe skin inflammation induced. Thus, the middle acid mantle zone of the SC plays an important protective role in the invasion of pathogenic bacteria.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Gasdermin a guards epidermal differentiation and cornification in skin barrier repair: Its role in atopic dermatitis pathogenesis (Room C (Nishiki) ) - Mar 4, 2023 - Abstract #ISID2023ISID_355;
Remarkably, the GSDMA expression is reduced in the epidermis of patients with AD compared to normal individuals. Gsdma1/a3-deficiency might be involved in AD pathogenesis, likely through GSDMA-mediated epidermal differentiation and cornification.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Propionate alleviates itch in atopic dermatitis by modulating sensory TRP channels of dorsal root ganglion (Room A (Concord Ballroom) ) - Mar 4, 2023 - Abstract #ISID2023ISID_324;
Gsdma1/a3-deficiency might be involved in AD pathogenesis, likely through GSDMA-mediated epidermal differentiation and cornification. Propionate reduced the responsiveness of dorsal root ganglion neurons to pruritogens in vitro , attenuated MC903-induced hyper-excitability in sensory neurons, and inhibited capsaicin-evoked hTRPV1 currents (IC50=20.08

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Involucrin/ck1e/vitamin D receptor regulatory axis underlies evolution of human epidermis out of Africa (Room F (Harmony) ) - Mar 4, 2023 - Abstract #ISID2023ISID_302;
Ivl-/- mouse skin treated with MC903 (vitamin D agonist) exhibited a dampened Vdr response with notable decreased Vdr expressions in multiple scRNA-seq-identified keratinocyte populations...Together, our mouse-to-human translational studies identify a conserved Ivl/CK1e/VDR regulatory axis that underlies human skin evolution out of Africa. Our findings further highlights population-specific, molecular diversity for the human epidermis.

|||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Tralokinumab improves signs, symptoms, and key biomarkers in patients of different racial subgroups with atopic dermatitis (Room F (Harmony) ) - Mar 4, 2023 - Abstract #ISID2023ISID_300;
P3
In skin, gene expression of IL13RA1, IL4R, CCL2, and DPP4 was higher in Asian compared to White patients. Tralokinumab shifted biomarker expression, reduced S. aureus abundance, and improved signs/symptoms of AD across all racial subgroups over 16 weeks.

|||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Dovonex (calcipotriol) / LEO Pharma, Novartis, Xeljanz (tofacitinib) / Pfizer
Topical administration of MDI1228, a novel pan-JAK inhibitor, effectively suppresses the development of skin inflammation in mice (Room E (Moonlight) ) - Mar 4, 2023 - Abstract #ISID2023ISID_286;
Taken together, we have shown that MDI1228, a pan-JAK inhibitor, has broad spectrum inhibitory effect on activation of the immune system mediated by key cytokines including IFN?, IFN?, IL4 and/or IL17A, and as a result it effectively suppresses the development of both allergic and autoimmune skin inflammation. These results indicate that MDI1228 is a promising candidate for topical anti-inflammatory drug for various types of dermatitis.

|||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Linear ubiquitin chain assembly complex (LUBAC) is involved in the development of murine imiquimod (IMQ)-induced and IL-23-induced psoriasis models (Room D (Ohgi) ) - Mar 4, 2023 - Abstract #ISID2023ISID_267;
These results indicate that the canonical NF-?B pathway in radio-resistant cells is important for the pathogenesis in IMQ-induced psoriasis model. While NF-?B in immune cells such as T cells is important in some inflammatory skin diseases, our findings suggested that NF-?B even in non-immune cells such as keratinocytes may be important in the development of psoriasis.

|||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Loss of both host-derived antimicrobial peptides and bacteriocin-producing commensals enables survival of Staphylococcus aureus on Th2-inflamed skin (Room D (Ohgi) ) - Mar 4, 2023 - Abstract #ISID2023ISID_262;
To understand why increased AMPs in AD compared to normal skin would enable increased S. aureus we analyzed the skin of Il4ra -/- or WT mice with or without MC903-induced Th2 inflammation...Notably, the selective killing of CoNS-Bac + was rescued on the skin of Camp -/- mice with Th2 inflammation. These results show that the combination of both a partial loss of host AMPs and elimination of CoNS-Bac + during Th2 inflammation can explain why S. aureus expands on AD skin.

|||||||||| Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma
Efficacy and safety of delgocitinib cream in adults with moderate-to-severe chronic hand eczema: results of the Phase 3 DELTA 1 trial (New Orleans Theater B) - Mar 4, 2023 - Abstract #AAD2023AAD_3207;

|||||||||| The Psoriasis Study of Health Outcomes (PSoHO) in biologic-na () - Mar 4, 2023 - Abstract #AAD2023AAD_3023;
These results show that the combination of both a partial loss of host AMPs and elimination of CoNS-Bac + during Th2 inflammation can explain why S. aureus expands on AD skin. Responses ?PASI90 and/or sPGA0/1 were reported in 77% of patients treated with an anti-IL-17A (ixekizumab 79%, secukinumab 70%) and 61% with other biologics (ustekinumab 51%, brodalumab 71%, adalimumab 57%, guselkumab 70%, risankizumab 67%, tildrakizumab 63%) among bio-na

|||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Post hoc Analysis of Long-term Efficacy of Brodalumab in Early vs Late Responders With Psoriasis () - Mar 4, 2023 - Abstract #AAD2023AAD_3014;
Patients were initially randomized to brodalumab every 2 weeks, ustekinumab, or placebo. PASI 75/90/100 rates between early and late responders were comparable by 120 weeks, supporting the long-term efficacy of brodalumab.



	Diseases Companies Products Productz Mechanisms of Action Sites